Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results EsoGuard ® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter Con
How this was made
The 30-second read
Why it matters
The earnings release provides the first detailed financial picture of the company's post‑reimbursement phase, offering traders fresh data on revenue trajectory and cash position.
Market read
First‑time Medicare coverage for EsoGuard and record test volumes are positive catalysts, but the reported loss and modest revenue keep short‑term sentiment cautious.
What to watch
The $15M private placement and upcoming LCD decision could provide additional liquidity and regulatory clarity.
Lucid Diagnostics reports Q3 2026 revenue of $1,203 thousand as first Medicare payments for EsoGuard arrive in October
GAAP net loss narrowed to $(6,677) thousand from $(10,397) thousand, but the company's reconciliation shows a change in fair value of convertible debt of (5,541) thousand within other income. Revenue was $1,203 thousand against $1,211 thousand a year earlier, operating expenses rose to 13,479 thousand from 12,970 thousand, and the non-GAAP adjusted loss was $(10,599) thousand against $(10,300) thousand. Cash fell to $18.0 million from $34.7 million at December 31, 2025, before a $15.0 million Series C financing closed after quarter end.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended Sept 30, 2026GAAP | $1.20M | – | – |
| Total operating expenses, three monthsGAAP | 13.48M | – | – |
| Cost of revenues, three monthsGAAP | 1.40M | – | – |
| Sales and marketing, three monthsGAAP | 5.25M | – | – |
| General and administrative, three monthsGAAP | 5.54M | – | – |
| Research and development, three monthsGAAP | 1.18M | – | – |
| Other (income) expense, net, three monthsGAAP | −5.60M | – | – |
| Net loss, three monthsGAAP | −$6.68M | – | – |
| Net loss per common share, basic and diluted, three monthsGAAP | $(0.03) | – | – |
| Net loss attributable to common stockholders, three monthsGAAP | −6.68M | – | – |
| EBITDA, three monthsnon-GAAP | −6.51M | – | – |
| Non-GAAP adjusted loss, three monthsnon-GAAP | −$10.60M | – | – |
| Non-GAAP adjusted loss per share, three monthsnon-GAAP | $(0.06) | – | – |
| Net operating expenses (non-GAAP), three monthsnon-GAAP | $11.80M | – | – |
| Revenue, nine months ended Sept 30, 2026GAAP | $3.93M | – | – |
| Total operating expenses, nine monthsGAAP | 41.12M | – | – |
| Cost of revenues, nine monthsGAAP | 4.47M | – | – |
| Sales and marketing, nine monthsGAAP | 16.03M | – | – |
| General and administrative, nine monthsGAAP | 16.72M | – | – |
| Research and development, nine monthsGAAP | 3.58M | – | – |
| Other (income) expense, net, nine monthsGAAP | −4.92M | – | – |
| Net loss, nine monthsGAAP | −$32.27M | – | – |
| Net loss per common share, basic and diluted, nine monthsGAAP | $(0.26) | – | – |
| Net loss attributable to common stockholders, nine monthsGAAP | −45.02M | – | – |
| Preferred stock dividends and deemed dividends, nine monthsGAAP | 12.75M | – | – |
| EBITDA, nine monthsnon-GAAP | −31.80M | – | – |
| Non-GAAP adjusted loss, nine monthsnon-GAAP | −$31.91M | – | – |
| Non-GAAP adjusted loss per share, nine monthsnon-GAAP | $(0.19) | – | – |
| Net operating expenses (non-GAAP), nine monthsnon-GAAP | $35.84M | – | – |
| Cash and cash equivalents, as of Sept 30, 2026other | $18M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| EsoGuard (sole reported revenue line)The company states it performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26, and that October was a record month with more than 1,800 tests. The filing does not print a prior-year EsoGuard revenue figure or a percentage change. | $1.2 million (three months ended Sept 30, 2026) | – | – |
Capital returns
- No share repurchases or dividends on common stock are reported in the filing.
- The release cites a $15.0 million private placement to existing long-term investors under the highlight 'Strengthened balance sheet'. The release does not state its closing date within the quarter.
- After quarter end, Lucid closed a $15.0 million Series C Convertible Preferred Stock financing.
- Basic and diluted shares outstanding (weighted) were 190,945 thousand for the three months ended Sept 30, 2026, against 108,176 thousand a year earlier, and 171,575 thousand for the nine months against 92,131 thousand.
What drove it
- Medicare coverage: the company states that it received first Medicare payments for EsoGuard in October, that claims were submitted from late September after a meeting with Novitas, and that payments have been received at the Clinical Laboratory Fee Schedule rate of $1,938.01 per test. The company states this coverage is independent of the pending MolDX LCD reconsideration.
- Test volume: the company states it performed 2,871 EsoGuard tests in 3Q26, that October was a record month with more than 1,800 tests, and that more than 50,000 tests have been performed since launch.
- Commercial coverage: the company states that five Concert client health plans are expected to have formally adopted the Concert EsoGuard coverage policy by year-end, including the three previously reported.
- Veterans Affairs: the company states it launched its first two U.S. Department of Veterans Affairs programs and expects the VA to be a meaningful long-term contributor.
- Guidelines and coding: the company cites a draft AGA Barrett's esophagus guideline naming EsoGuard and EsoCheck as an alternative to endoscopy, a new Category III CPT code for EsoCheck cell collection, and a proposed ICD-10 code for positive EsoGuard results.
- Study: the company announced publication of an 11,991-patient real-world EsoGuard study and states sampling with EsoCheck was successful in 95% of patients.
- Other income: the company's reconciliation shows other (income) expense, net of (5,599) thousand for the quarter, including a change in fair value of convertible debt of (5,541) thousand, which the company classifies as a non-cash or financing related item.
Concerns
- Revenue was $1,203 thousand for the quarter against $1,211 thousand a year earlier, and 3Q26 is the first quarter reported with Medicare payments in place, so the revenue base remains very small.
- Operating expenses rose to 13,479 thousand from 12,970 thousand, with sales and marketing up to 5,252 thousand from 4,291 thousand.
- The GAAP net loss narrowed mainly against a non-operating line. The reconciliation shows the change in fair value of convertible debt at (5,541) thousand, while the non-GAAP adjusted loss was $(10,599) thousand against $(10,300) thousand a year earlier.
- Cash fell to $18.0 million from $34.7 million at December 31, 2025. The $15.0 million Series C financing closed after quarter end.
- The MolDX LCD reconsideration for EsoGuard remains pending. The company states that it expects the draft LCD to be published as an administrative backlog clears, but no date is given.
What to watch
- Whether October's reported volume of more than 1,800 tests converts into reported revenue in the fourth quarter, since the release gives no revenue guidance.
- Publication of the draft MolDX LCD for EsoGuard, which the company describes as expected when the backlog clears.
- Adoption of the Concert EsoGuard coverage policy by the five Concert client health plans by year-end.
- Growth in VA programs beyond the first two launched.
- Trend in operating expenses against revenue, given that sales and marketing rose year over year in the quarter.
- Cash position and the use of the $15.0 million Series C proceeds, since the release does not state a cash runway or a quarter-end outlook.
Balance sheet and cash flow
- Cash and cash equivalents were $18.0 million as of September 30, 2026, compared with $34.7 million as of December 31, 2025.
- Operating cash flow, free cash flow, total assets, total equity and total debt are not printed in the release.
- Preferred stock dividends and deemed dividends were 12,747 thousand for the nine months ended Sept 30, 2026, against 12,559 thousand a year earlier, with no amount shown for the three-month period.
Analysis
Lucid reported third-quarter 2026 revenue of $1,203 thousand, against $1,211 thousand in the prior-year quarter, and a GAAP net loss of $(6,677) thousand, or $(0.03) per share, against $(10,397) thousand, or $(0.10) per share. The narrower GAAP loss is not explained by operations in the filing. The reconciliation shows other (income) expense, net of (5,599) thousand, which includes a change in fair value of convertible debt of (5,541) thousand. Operating expenses rose to 13,479 thousand from 12,970 thousand. Sales and marketing was 5,252 thousand against 4,291 thousand, while cost of revenues and research and development declined. The non-GAAP adjusted loss was $(10,599) thousand, or $(0.06) per share, against $(10,300) thousand, or $(0.10) per share. The company states that this measure illustrates the effect of stock-based compensation and other non-cash income and expenses.
The release frames the period as a transition from a reimbursement constraint to a commercial one. The company states that Medicare claims began in late September and that first payments were received in October at the Clinical Laboratory Fee Schedule rate of $1,938.01 per test. It reports 2,871 EsoGuard tests in the quarter and more than 1,800 in October. The company also says this Medicare coverage is independent of the pending MolDX LCD reconsideration. Revenue for the quarter was still only $1.2 million, so the fourth-quarter figure will be the first test of whether the reported October volume turns into recognized revenue.
For the nine months, revenue was $3,932 thousand against $3,202 thousand, and the GAAP net loss was $(32,273) thousand against $(41,744) thousand. Sales and marketing for the nine months rose to 16,029 thousand from 12,367 thousand, while general and administrative fell to 16,723 thousand from 17,383 thousand. The nine-month GAAP loss attributable to common stockholders was $(45,020) thousand after 12,747 thousand of preferred dividends and deemed dividends, compared with $(54,303) thousand a year earlier.
On capital, cash was $18.0 million at September 30, 2026, against $34.7 million at December 31, 2025. The company cites a $15.0 million private placement in the quarter and a $15.0 million Series C Convertible Preferred Stock financing closed after quarter end. Weighted basic and diluted shares rose to 190,945 thousand from 108,176 thousand for the quarter. The release gives no guidance, no cash runway, and no operating cash flow figure, so the financing needs cannot be measured from the document.
The main points for a reader are the Medicare payment start, the size of the revenue base, operating expense growth, and a cash position that was reduced before the post-quarter financing. The company's own description is that near-term growth now depends on commercial execution, and the release provides no quantified outlook against which to measure it.
Management, verbatim
“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test,”
Lishan Aklog, M.D., Chairman and Chief Executive Officer, Lucid Diagnostics
“Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer, Lucid Diagnostics
Not in the filing
stated, not guessed- No revenue, expense, margin or other financial guidance is provided for Q4 2026 or FY2026.
- Percentage changes year over year and sequential changes are not printed for any metric.
- Prior-quarter (Q2 2026) figures are not printed in the release.
- Prior-year EsoGuard revenue is not printed as a separate figure.
- Gross margin is not printed; only cost of revenues is given.
- Operating cash flow, free cash flow, total assets, total equity and total debt are not printed.
- The cash figure of $34.7 million is at December 31, 2025, not a prior-year quarter-end, so no prior-year balance sheet comparison is provided.
- The closing date and cash proceeds timing of the $15.0 million private placement within the quarter are not stated.
- The per-share and share count figures for the prior quarter are not printed.
- No consensus estimates, analyst expectations or share-price reaction are provided in the filing.
- No previous outlook was supplied, so vs_prior_guidance is empty.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Lucid Diagnostics is a commercial‑stage cancer‑prevention diagnostics company and a subsidiary of PAVmed.
Ticker impact
Lucid Diagnostics disclosed Q3 2026 results with $1.2M revenue, $6.7M GAAP loss and first Medicare payments for EsoGuard.
likely downward pressure as investors digest loss, tempered by potential revenue growth from Medicare coverage
The company posted a net loss and modest revenue, but the new Medicare reimbursement and record test volume suggest a longer‑term growth catalyst.
Market effects
Highlights growing Medicare reimbursement for cancer‑prevention diagnostics, may boost other med‑tech firms in the same space.
U.S. healthcare investors may adjust exposure to diagnostic companies awaiting payer coverage decisions.
Limited; primarily affects U.S. biotech and healthcare sectors.
Counterpoint
Despite the loss, the Medicare reimbursement could accelerate revenue growth faster than anticipated.
Key entities
- companyLucid Diagnostics Inc.
Nasdaq‑listed diagnostic firm reporting Q3 2026 results.
- parent_companyPAVmed Inc.
Parent company of Lucid Diagnostics.
